<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Curvebeam AI Ltd. ( (AU:CVB) ) has shared an update. CurveBeam AI has appointed U.S.-based orthopaedic industry veteran Patrick Fisher as an independent non-executive director, adding extensive leadership experience from Orthofix, Stryker and Wright Medical. Fisher’s background in global orthopaedic markets, capital equipment deployment and surgeon engagement is expected to support the broader rollout of CurveBeam’s weight-bearing CT technology. The company’s chair said Fisher’s appointment strengthens strategic capabilities in the key U.S. growth market as CurveBeam executes its next phase of commercial expansion. Fisher, who will receive a mix of cash fees and time-vested share rights, highlighted plans to help drive partnerships, market adoption and sustained growth in the U.S. and internationally. The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page. More about Curvebeam AI Ltd. CurveBeam AI Limited is a medical imaging company that develops, manufactures and sells specialised CT scanners combined with AI-enabled SaaS clinical assessment tools for musculoskeletal care. Its flagship HiRise system performs weight-bearing and traditional CT scans, targeting orthopaedic and related markets from bases in Melbourne and Hatfield, Pennsylvania. Average Trading Volume: 851,116 Technical Sentiment Signal: Sell Current Market Cap: A$27.71M See more insights into CVB stock on TipRanks’ Stock Analysis page.</div>

LABU

IBBQ

BEAM

SBIO

CurveBeam AI Ltd. has appointed Patrick Fisher, a veteran in the orthopaedic industry, as an independent non-executive director to enhance its strategic capabilities in the U.S. market. Fisher's experience from companies like Orthofix and Stryker will support the rollout of CurveBeam's weight-bearing CT technology. His role includes driving partnerships and market adoption for growth both in the U.S. and internationally. The current analyst rating for CurveBeam AI stock (AU:CVB) is a Hold with a price target of A$0.15.

CurveBeam AI Adds Veteran Orthopaedic Executive to Board for Global Growth Push